New Pivotal Data Demonstrate Clinical Benefit of Roche’s Glofitamab, a Potential First-in-Class Bispecific Antibody for People with Aggressive Lymphoma
Data to be presented for the first time at ASCO and EHA 2022 show glofitamab induces high and durable complete response rates in people with heavily pre-treated diffuse large B-cell… Read More



